Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 3, 2007 - Issue 4
Submit an article Journal homepage
475
Views
88
CrossRef citations to date
0
Altmetric
Review

Alterations in drug disposition during pregnancy:

implications for drug therapy

Lucy S Hodge University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy, 7-115B Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN 55455, USA +1 612 625 7665; +1 612 625 3927; [email protected]
, PharmD &
Timothy S Tracy
, PhD
Pages 557-571 | Published online: 19 Oct 2007

Bibliography

  • REFUERZO JS, BLACKWELL SC, SOKOL RJ et al.: Use of over-the-counter medications and herbal remedies in pregnancy. Am. J. Perinatol. (2005) 22(6):321-324.
  • GLOVER DD, AMONKAR M, RYBECK BF, TRACY TS: Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am. J. Obstet. Gynecol. (2003) 188(4):1039-1045.
  • LEE E, MANENO MK, SMITH L: National patterns of medication use during pregnancy. Pharmacoepidemiol. Drug Saf. (2006) 15:537-545.
  • HOSTETTER A, STOWE ZN, STRADER JR, MCLAUGHLIN E, LLEWELLYN A: Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress. Anxiety (2000) 11:51-57.
  • PENNELL PB, NEWPORT DJ, STOWE ZN, HELMERS SL, MONTGOMERY JQ, HENRY TR: The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology (2004) 62:292-295.
  • TSUTSUMI K, TSUTOMU K, MATSUKI S et al.: The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin. Pharmacol. Ther. (2001) 70:121-125.
  • TRACY TS, VENKATARAMANAN R, GLOVER DD, CARITIS SN: Temporal changes in drug metabolism (CYP1A2, CYP2D6, and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol. (2005) 192:633-639.
  • MCGILL H: Sex steroid hormone receptors in the cardiovascular system. Postgraduate Med. J. (1989):64-68.
  • MATTISON DR, BLANN E, MALEK A: Physiological alterations during pregnancy: impact on toxicokinetics. Toxicologic. Sci. (1991):215-218.
  • ROBSON SC, HUNTER S, BOYS RJ: Serial study of factors influencing changes in cardiac output during human pregnancy. Am. J. Physiol. (1989) 256:H1060-H1065.
  • CLAPP JE, CAPELESS EL: Cardiovascular function before, during, and after the first and subsequent pregnancies. Am. J. Cardiol. (1997) 80:1469-1473.
  • THEUNISSEN IM, PARER JT: Fluid and electrolytes in pregnancy. Clin. Obstet. Gynecol. (1994) 37:3-15.
  • NAKAI A, SEKIYA I, OYA A, KOHINO T, ARAKI T: Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch. Gynecl. Obstet. (2002) 266:25-29.
  • SMITH MT, LIVINGSTONE I, EADIE MJ, HOOPER WD, TRIGGS EJ: Chronic propranolol administration during pregnancy. Maternal pharmacokinetics. Eur. J. Clin. Pharmacol. (2007) 25(4):481-490.
  • GERDIN E, SALMONSON T, LINDBERG B: Maternal kinetics of morphine during labour. J. Perinatal Med. (1990) 18(6):479-487.
  • CHEUNG CK, LAO T, SWAMINATHAN R: Urinary excretion of some proteins and enzymes during normal pregnancy. Clin. Chem. (1989) 35(9):1978-1980.
  • ERMAN A, NERI A, SHARONI R et al.: Enhanced urinary albumin excretion after 35 weeks of gestation and during labour in normal pregnancy. Scand. J. Clin. Lab. Invest. (1992) 52(5):409-413.
  • HAYASHI M, UEDA Y, HOSHIMOTO K et al.: Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. Am. J. Kidney Dis. (2002) 39(2):392-400.
  • DEAN M, BERESFORD S, PATTERSON RJ, LEVY G: Serum protein binding of drugs during and after pregnancy in humans. Clin. Pharmacol. Ther.(1980) 28:253-261.
  • JEYABALAN A, CONRAD KP: Renal function during normal pregnancy and preeclampsia. Front. Biosci. (2007) 12:2425-2437.
  • VARGA I, RIGO J, SOMOS P, JOO JG, NAGY B: Analysis of maternal circulation and renal function in physiologic pregnancies; Parallel examinations of the changes in the cardiac output and the glomerular filtration rate. J. Matern. Fetal Med. (2000) 9:97-104.
  • DUVEKOT JJ, CHERIEX EC, PIETERS FA, MENHEERE P, PEETERS L: Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. J. Obstet. Gynecol. (1993) 169:1382-1392.
  • DAVISON JM, NOBLE MC: Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br. J. Obstet. Gynaecol. (1981) 88:10-17.
  • HEBERT MF, CARR DB, ANDERSON GD et al.: Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. Pharmacokinet. Pharmacodynamic (2005) 45:25-33.
  • SCHOU M, AMIDSEN A, STEENSTRUP OR: Lithium and pregnancy: Hazards to women given lithium during pregnancy and delivery. Br. Med. J. (1973) 25:117-121.
  • LUXFORD AM, KELLAWAY GS: Pharmacokinetics of digoxin in pregnancy. Eur. J. Clin. Pharmacol. (1983) 25:117-121.
  • FUHR U, ROST KL, ENGELHARDT R, SACHS M, LIERMANN D, BELLOC C: Evaluation of caffeine as a test drug for CYP1A2, NAT2, and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics (1996) 6:159-176.
  • BRACKEN MB, TRICHE EW, BELANGER K, HELLENBRAND K, LEADERER BP: Association of maternal caffeine consumption with decrements in fetal growth. Am. J. Epidemiol. (2003) 157(5):456-466.
  • KNUTTI R, ROTHWEILER H, SCHLATTER C: Effect of pregnancy on the pharmacokinetics of caffeine. Eur. J. Clin. Pharmacol. (1981) 21:121-126.
  • BOLOGA M, TANG B, KLEIN J, TESORO A, KOREN G: Pregnancy-induced changes in drug metabolism in epileptic women. J. Pharmacol. Exp. Ther. (1990) 257(2):735-740.
  • ALDRIDGE A, BAILEY J, NEIMS A: The disposition of caffeine during and after pregnancy. Semin. Perinatol. (1981) 5(4):310-313.
  • BRAZIER JL, RITTER J, BERLAND M, KHENFER D, FAUCON G: Pharmacokinetics of caffeine during and after pregnancy. Dev. Pharmacol. (1983) 6:315-322.
  • GRANFORS MT, BACKMAN JT, LAITILA J, NEUVONEN PJ: Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin. Pharmacol. Ther. (2005) 78(4):400-411.
  • ABERNETHY DR, TODD EL: Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur. J. Clin. Pharmacol. (1985) 28:425-428.
  • CARILLO JA, BENITEZ J: CYP1A2 activity, gender and smoking as variables influencing toxicity of caffeine. Br. J. Clin. Pharmacol. (1996) 41:605-608.
  • KALOW W, TANG BK: Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. (1991) 49(1):44-88.
  • HAN X, OU-YANG D, LU P et al.: Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics (2001) 11:429-435.
  • GARDNER MJ, SCHATZ M, COUSINS L, ZEIGER R, MIDDLETON E, JUSKO WJ: Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur. J. Clin. Pharmacol. (1987) 32(3):289-295.
  • CARTER BL, DRISCOLL CE, SMITH GD: Theophylline clearance during pregnancy. Obstet. Gynecol. (1986) 68(4):555-559.
  • DIXON CM, COLTHUP PV, SERABJIT-SINGH CJ, KERR BM, PARK GR, TARBIT MH: Multiple forms of cytorchrome P450 are involved in metabolism of ondansetron in humans. Drug Metab. Dispos. (1995) 23(11):1225-1230.
  • CALLAGHAN JT, BERGSTROM RF, PTAK LR, BEASLEY CM: Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. (1999) 37(3):177-193.
  • BERTILSSON L, CARRILLO JA, DAHL ML et al.: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. (1994) 38:471-473.
  • WANG RW, LIU L, CHENG H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metabol. Dispos. (1996) 24(7):786-791.
  • MESSINA ES, TYNDALE RF, SELLERS EM: A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. (1997) 282:1608-1614.
  • DEMPSEY D, JACOB P, BENOWITZ NL: Accelerated metabolism of nicotine and cotinine in smokers. J. Pharmacol. Exp. Ther. (2002) 301:594-598.
  • REBAGLIATO M, BOLUMAR F, FLOREY CV et al.: Variations in cotinine levels in smokers during and after pregnancy. Obstet. Gynecol. (1998) 178:568-571.
  • ONCKEN CA, HATSUKAMI DK, LUPO VR, LANDO HA, GIBEAU LM, HANSEN RJ: Effects of short-term use of nicotine gum in pregnant smokers. Clin. Pharmacol. Ther. (1996) 59:654-661.
  • OGBURN PL, HURT RD, CROGHAN IT et al.: Nicotine patch use in pregnant smokers: nicotine and cotinine levels and fetal effects. Am. J. Obstet. Gynecol. (1999) 181:736-743.
  • BENOWITZ NL, LESSOV-SCHLAGGAR CN, SWAN GE, JACOB P: Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. (2006) 79(5):480-488.
  • ANDERSON G: Pharmacy-induced changes in pharmacokinetics. Clin. Pharmacokinet. (2005) 44(10):989-1008.
  • TOMSON T, LINDBOM U, EKQVIST B, SUNDQVIST A: Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia (1994) 1:131-135.
  • YERBY MS, FRIEL PN, MCCORMICK K et al.: Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding. Epilepsy Res. (1990) 5:223-228.
  • KNOTT C, WILLIAMS CP, REYNOLDS F: Phenytoin kinetics during pregnancy and the puerperium. Br. J. Clin. Pharmacol. (1986) 93:1030-1037.
  • CHEN SS, PERUCCA E, LEE JN, RICHENS A: Serum protein binding and free concentrations of phenytoin and phenobarbitone in pregnancy. Br. J. Clin. Pharmacol. (1982) 13:547-552.
  • NA-BANGCHANG K, MANYANDO C, RUENGWEERAYUT R et al.: The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant woman. Eur. J. Clin. Pharmacol. (2005) 61:573-582.
  • MCGREADY R, STEPNIEWSKA K, SEATON E et al.: Pregnancy and use of oral contraceptives reduces biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. (2003) 59:553-557.
  • VAN HEESWIJK RPG, KHALIQ Y, GALLICANO KD et al.: The pharmacokinetics of nelfinavir and M8 during pregnancy and post-partum. Clin. Pharmacol. Ther. (2004) 76:588-597.
  • HIRT D, TRELUYER JM, JULLIEN V et al.: Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrobial Agents Chemother. (2006) 50(6):2079-2086.
  • PALOVAARA S, TYBRING G, LAINE K: The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br. J. Clin. Pharmacol. (2003) 56:232-237.
  • HAGG S, SPIGSET O, DAHLQVIST R: Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 51:169-173.
  • HOGSTEDT S, LINDBERG B, RANE A: Increased oral clearance of metoprolol in pregnancy. Eur. J. Clin. Pharmacol. (1983) (24):217-220.
  • HOGSTEDT S, LINDBERG B, PENG DR, REGARDH CG, RANE A: Pregnancy-induced increase in metoprolol metabolism. Clin. Pharmacol. Ther. (1985) (37):688-692.
  • WADELIUS M, DARJ E, FRENNE G, RANE A: Induction of CYP2D6 during pregnancy. Clin. Pharmacol. Ther. (1997) 62:400-407.
  • HEIKKINEN T, EKBLAD U, KERO P, EKBLAD S, LAINE K: Citalopram in pregnancy and lactation. Clin. Pharmacol. Ther. (2002) (72):184-191.
  • HEIKKINEN T, EKBLAD S, PALO P: Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin. Pharmacol. Ther. (2003) 73:330-337.
  • PREVOST RR, AKL SA, WHYBREW D, SIBAI BM: Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy (1992) 12(3):174-177.
  • BARTON JR, PREVOST RR, WILSON DA, WHYBREW WD, SIBAI BM: Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am. J. Obstet. Gynecol. (1991) 165(4):951-954.
  • WOLFF K, BOYS A, ROSTAMI-HODJEGAN A, HAY A, RAISTRICK D: Changes to methadone clearance during pregnancy. Eur. J. Clin. Pharmacol. (2005) 61:763-768.
  • POND SM, KREEK MJ, TONG TG, RAGHUNATH J, BENOWITZ NL: Altered methadone pharmacokinetics in methadone-maintained pregnant women. J. Pharmacol. Exp. Ther. (1985) 233(1):1-6.
  • KOSEL BW, BECKERMAN KP, HAYASHI S, HOMMA M, AWEEKA FT: Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS (2003) 17:1195-1199.
  • OHKITA C, GOTO M: Increased 6-hydroxycortisol excretion in pregnant women: implication of drug-metabolizing enzyme induction. DICP (1990) 24:814-816.
  • ZHANG H, CUI D, WANG B et al.: Pharmacokinetic drug interactions involving 17α–ethinylestradiol: a new look at an old drug. Clin. Pharmacokinet. (2007) 46(2):133-157.
  • ZHANG JW, LIU Y, LI W, HAO DC, YANG L: Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur. J. Clin. Pharmacol. (2006) 62:497-502.
  • PALOVAARA S, KIVISTO KT, TAPANAINEN P, MANNINEN P, NEUVONEN PJ, LAINE K: Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′hydroxylation. J. Clin. Pharmacol. (2000) 50:333-337.
  • BALOGH A, GESSINGER S, SVAROVSKY U et al.: Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur. J. Clin. Pharmacol. (1998) 54:729-734.
  • LIN HL, KENT UM, HOLLENBERG PF: Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. (2002) 301(1):160-167.
  • PETRENAITE V, SABERS A, HANSEN-SCHWARTZ J: Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. (2005) 65:185-188.
  • DE HAAN GJ, EDELBROEK P, SEGERS J et al.: Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy. Neurology (2004) 63:571-573.
  • PAPINI O, PEREIRA DA CUNHA S, CARMO DA SILVA MATHES A et al.: Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. J. Pharm. Biomed. Anal. (2006) 40:397-403.
  • BEAULAC-BAILLARGEON L, ROCHELEAU S: Paracetamol pharmacokinetics during the first trimester of human pregnancy. Eur. J. Clin. Pharmacol. (1994) 46(5):451-454.
  • MINERS JO, ROBSON RA, BIRKETT DJ: Paracetamol metabolism in pregnancy. Br. J. Clin. Pharmacol. (1986) 22(3):359-362.
  • REIMERS A, HELDE G, BRODTKORB E: Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia (2005) 46 (9):1414-1417.
  • ABERNETHY DR, DIVOLL M, OCHS HR, AMEER B, GREENBLATT DJ: Increased metabolic clearance of acetminophen with oral contraceptive use. Obstet. Gynecol. (1982) 60(3):338-341.
  • CHEN S, BEATON D, NGUYEN N et al.: Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J. Biologic. Chem. (2005) 280(45):37547-37557.
  • SHELEPOVA T, NAFZIGER AN, VICTORY J et al.: Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the Cooperstown 5+1 cocktail. J. Clin. Pharmacol. (2005) 45:1413-1421.
  • MEIGS RA, RYAN KJ: Cytochrome P-450 and steroid biosyntehsis in the human placenta. Biochim. Biophys. Acta (1968) 165:476-482.
  • SYME MR, PAXTON JW, KEELAN JA: Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. (2004) 43(8):487-514.
  • COLLIER AC, TINGLE MD, PAXTON JW, MITCHELL MD, KEELAN JA: Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod. (2002) 17(10):2564-2572.
  • PASANEN M, HAAPARANTA T, SUNDIN M, SIVONEN P, VAHAKANGAS K, RAUNIO H: Immunochemical and molecular biological studies on human placental cigarette smoke-inducible cytochrome P-450 dependent monooxygenase activities. Toxicology (1990) 62:175-187.
  • LAGUEUX J, PEREG D, AYOTTE P, DEWAILLY E, POIRIER GG: Cytochrome P450 CYP1A1 enzyme activity and DNA adducts in placenta of women environmentally exposed to organochlorines. Environ. Res. (1999) 80:369-382.
  • WHYATT RM, BELL DA, JEDRYCHOWSKI W et al.: Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. Carcinogenesis (1998) 19:1389-1392.
  • ZDRAVKOVIC T, GENBACEV O, MCMASTER MT, FISHER SJ: The adverse effects of maternal smoking on the human placenta: a review. Placenta (2005) 26:S81-S86.
  • MANCHESTER DK, GORDON SK, GOLAS CL, ROBERTS EA, OKEY AB: Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanterene and benzo(a)pyrene. Cancer Res. (1987) 47:4861-4868.
  • HAKKOLA J, PASANEN M, PELKONEN O et al.: Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis (1997) 18(2):391-397.
  • PASANEN M, PELKONEN O: Xenobiotic and steroid-metabolising mooxygeases catalysed by cytochrome P450 and glutathione-S-transferase conjugations in the human placenta and theft relationships to maternal cigarette smoking. Placenta (1990) 11:75-85.
  • HAKKOLA J, RAUNIO H, PURKUNEN R et al.: Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. (1996) 52:379-383.
  • KARL P, GORDON B, LEIBER C: Acetaldehyde production and transfer in the perfused human placental cotyledon. Science (1988) 242:273-275.
  • MCCARVER DG: ADH2 and CYP2E1 genetic polymorphisms: risk factors for alcohol-related birth defects. Drug Metab. Dispos. (2001) 29:562-565.
  • COLLIER AC, GANLEY NA, TINGLE MD et al.: UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem. Pharmacol. (2002) 63:409-419.
  • NISHIMURA M, NAITO S: Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab. Pharmacokinet. (2006) 21(5):357-374.
  • COLLIER AC, KEELAN JA, VAN ZIJL PE, PAXTON JW, MITCHELL MD, TINGLE MD: Human placental glucuronidation and transport of 3′-azido-3′-deoxythymidine and uridine diphosphate glucuronic acid. Drug Metab. Dispos. (2004) (32):813-820.
  • MCROBIE DJ, GLOVER DD, TRACY TS: Regiospecificity of placental metabolism by cytochromes P450 and glutathione-S-transferase. Gynecol. Obstet. Invest. (1996) 42(3):154-158.
  • GLOVER DD, MCROBIE DJ, TRACY TS: Effects of gestational and overt diabetes on placental cytochromes P450 and glutathione-S-transferase. Prim. Care Update Ob. Gyns. (1998) 5(4):189.
  • PACIFICI GM: Sulfation of drugs and hormones in mid-gestation human fetus. Early Hum. Dev. (2005) 81:573-581.
  • SODHA RJ, SCHNEIDER H: Sulphate conjugation of β-2-adrenoceptor stimulating drugs by platelet and placental phenol sulphotransferase. Br. J. Clin. Pharmacol. (1984) 17:106-108.
  • MYLLYNEN P, PASANEN M, PELKONEN O: Human placenta: a human organ for developmental toxicology research and biomonitoring. Placenta (2005) 26(5):361-371.
  • EVSEENKO D, PAXTON JW, KEELAN JA: Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin. Drug Metabol. Toxicol. (2006) 2(1):51-69.
  • GOTTESMAN M, PASTAN I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385-427.
  • CECKOVA-NOVOTNA M, PAVEK P, STAUD F: P-glycoprotein in the placenta: expression, localization, regulation, and function. Reprod.Toxicol. (2006) 22:400-410.
  • LANKAS GR, WISE LD, CARTWRIGHT ME, PIPPERT T, UMBENHAUER DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. (1998) 12:457-463.
  • SMIT JW, HUISMAN MT, VAN TELLINGEN O, WILTSHIRE HR, SCHINKEL AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (2007) 104:1441-1447.
  • KOLWANKAR D, GLOVER DD, WARE JA, TRACY TS: Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab. Dispos. (2005) 33:524-529.
  • HITZL M, SCHAEFFELER E, HOCHER B et al.: Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics (2004) 14:309-318.
  • GIL S, SAURA R, FORESTIER F, FARINOTTI R: P-glycoprotein expression of the human placenta during pregnancy. Placenta (2005) 26:268-270.
  • MATHIAS AA, HITTI J, UNADKAT JD: P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R963-R969.
  • MACFARLAND A, ABRAMOVICH DR, EWEN SW, PEARSON CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. (1994) 26(5):417-423.
  • ST-PIERRE MV, UGELE B, GAMBLING L, SHIVERICK KT: Mechanisms of drug transfer across the human placenta – a workshop report. Placenta (2002) 23(16):S159-S164.
  • ST-PIERRE MV, SERRANO MA, MACIAS RI et al.: Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Compar. Physiol. (2000) 279(4):R1495-R1503.
  • MEYER ZU SCHWABEDISSEN HE, GRUBE M, HEYDRICH B et al.: Expression, localization and function of MRP5 (ABCC5), a transporter for cyclic nucleotides in human placenta and cultured human trophoblasts. Am. J. Pathol. (2005) 166(1):39-48.
  • JOHNSON DR, FINCH RA, LIN ZP, ZEISS CJ, SARTORELLI AC: The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. (2001) 61(4):1469-1476.
  • MEYER ZU SCHWABEDISSEN HE, JEDLITSCHKY G, GRATZ M et al.: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Dispos. (2005) 33:896-904.
  • ALLIKMETS R, SCHRIML LM, HUTCHINSON A: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. (1998) 58:5337-5339.
  • JONKER JW, SMIT JW, BRINKHUIS RF et al.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Nat. Cancer Inst. (2000) 92:1651-1656.
  • WANG H, WU X, HUDKINS K et al.: Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissue from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am. J. Physiol Regul. Integr. Compar. Physiol. (2006) 291:E1295-E1304.
  • EVSEENKO DA, PAXTON JW, KEELAN JA: Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Dispos. (2007) 35(4):595-601.
  • SMITH AJ, VAN HELVOORT A, VAN MEER G et al.: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports, several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. (2000) 275(31):23530-23539.
  • BRAUNSTEIN GP: Endocrine changes of pregnancy. In: Williams Textbook of Endocrinology. Larsen PR, Kronenberg H, Melmed S, Polonsky K (Eds), Saunders Saint Louis, MO, USA (2003).
  • MCCARVER DG, HINES RN: The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. (2002) 300(2):361-366.
  • HAKKOLA J, TANAKA E, PELKONEN O: Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol. Toxicol. (1998) 82:209-217.
  • KITADA M, KAMATAKI T: Cytochrome P450 in human foetal liver: significance and foetal specific expression. Drug Metab. Rev. (1994) 26:305-323.
  • LACROIX D, SONNIER M, MONCION A, CHERON G, CRESTEIL T: Expression of CYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Clin. Pharmacol. (1997) 247:625-634.
  • OHMORI S, NAKASA H, ASANOME K et al.: Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta (1998) 1380(3):297-304.
  • KITADA M, KAMATAKI T, ITAHASHI K, RIKIHISA T, KANAKUBO Y: P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16α-hydroxylase of dehydroepiandrosterone 3-sulfate. J. Biologic. Chem. (1987) 262:13534-13537.
  • CHEN H, FANTEL AG, JUCHAU MR: Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab. Dispos. (2000) 28:1051-1057.
  • KOUKOURITAKI SB, MANRO JR, MARSH SA et al.: Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. (2004) 308(3):965-974.
  • TRELUYER JM, JACQZ-AIGRAIN E, ALVAREZ F, CRESTEIL T: Expression of CYP2D6 in developing human liver. Eur. J. Clin. Pharmacol. (1991) 202:583-588.
  • BURCHELL B, COUGHTRIE M, JACKSON M et al.: Development of human liver UDP-glucuronosyltransferase. Dev. Pharmacol. Ther. (1989) 13:70-77.
  • PACIFICI GM, SAWE J, KAGER L, RANE A: Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol. (1982) 22:553-558.
  • GARLAND M, ABILDSKOV KM, TAYLOR S et al.: Fetal morphine metabolism and clearance are constant during late gestation. Drug Metab. Dispos. (2006) 34:636-646.
  • PEARSON JG: Pharmacokinetics of glyburide. Am. J. Med. (1985) 79(3B):67-71.
  • BLUME H, DONATH F, WARNKE A: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. (2006) 29(9):769-784.
  • POND SM, KREEK MJ, TONG TG, RAGHUNAHTH J, BENOWITZ NL: Altered methadone pharmacokinetics in methadone maintained pregnant women. J. Pharmacol. Exp. Ther. (1985) 233(1):1-6.
  • VDAJA F, SOLINAS C, GRAHAM J, HITCHCOCK A, EADIE M: The case for lamotrigine monitoring during pregnancy. J. Clin. Neurosci. (2006) 13(1):103-104.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.